Shares of The Cooper Cos. (NYSE:COO) reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $179.97 and last traded at $178.30, with a volume of 241,919 shares trading hands. The stock had previously closed at $177.42.

A number of analysts have recently issued reports on COO shares. Jefferies Group restated a “buy” rating and set a $190.00 price objective (up from $175.00) on shares of The Cooper Cos. in a research report on Thursday, June 2nd. Cleveland Research upgraded The Cooper Cos. from a “neutral” rating to a “buy” rating in a research report on Monday, May 16th. Robert W. Baird reiterated a “buy” rating on shares of The Cooper Cos. in a research report on Tuesday, April 19th. TheStreet upgraded The Cooper Cos. from a “hold” rating to a “buy” rating in a research report on Friday, March 18th. Finally, Stifel Nicolaus upped their price target on The Cooper Cos. from $180.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, June 30th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $163.00.

The stock’s 50-day moving average is $165.88 and its 200 day moving average is $149.34. The stock has a market cap of $8.65 billion and a price-to-earnings ratio of 42.23.

The Cooper Cos. (NYSE:COO) last released its quarterly earnings results on Thursday, June 2nd. The medical device company reported $2.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.91 by $0.14. The firm had revenue of $484.80 million for the quarter. During the same period in the prior year, the firm posted $1.72 earnings per share. The company’s revenue was up 11.5% compared to the same quarter last year. On average, equities research analysts forecast that The Cooper Cos. will post $8.41 EPS for the current fiscal year.

In other The Cooper Cos. news, CEO Robert S. Weiss sold 151,839 shares of The Cooper Cos. stock in a transaction on Monday, June 27th. The stock was sold at an average price of $163.02, for a total value of $24,752,793.78. Following the completion of the transaction, the chief executive officer now directly owns 200,617 shares of the company’s stock, valued at approximately $32,704,583.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stanley Md Zinberg sold 10,000 shares of The Cooper Cos. stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $170.00, for a total value of $1,700,000.00. Following the completion of the transaction, the director now directly owns 899 shares of the company’s stock, valued at $152,830. The disclosure for this sale can be found here.

A number of institutional investors recently made changes to their positions in COO. I.G. Investment Management LTD. boosted its position in shares of The Cooper Cos. by 40.6% in the fourth quarter. I.G. Investment Management LTD. now owns 30,760 shares of the medical device company’s stock valued at $4,128,000 after buying an additional 8,884 shares in the last quarter. Andra AP fonden boosted its position in shares of The Cooper Cos. by 8.8% in the fourth quarter. Andra AP fonden now owns 9,900 shares of the medical device company’s stock valued at $1,329,000 after buying an additional 800 shares in the last quarter. Century Capital Management LLC boosted its position in shares of The Cooper Cos. by 3.1% in the fourth quarter. Century Capital Management LLC now owns 131,227 shares of the medical device company’s stock valued at $17,611,000 after buying an additional 3,912 shares in the last quarter. Schroder Investment Management Group boosted its position in shares of The Cooper Cos. by 13.1% in the fourth quarter. Schroder Investment Management Group now owns 307,100 shares of the medical device company’s stock valued at $41,213,000 after buying an additional 35,600 shares in the last quarter. Finally, WCM Investment Management CA boosted its position in shares of The Cooper Cos. by 64.6% in the fourth quarter. WCM Investment Management CA now owns 210,426 shares of the medical device company’s stock valued at $28,239,000 after buying an additional 82,555 shares in the last quarter.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.